Harmony Biosciences Holdings, I (HRMY) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Wait for pullback to $30.14. Recent C-suite change — blocks BUY_NOW at $32.24. Engine's entry $30.14 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: WAKIX (98.0%); Concentration risk — Supplier: Bioprojet.
Harmony Biosciences is a neuroscience company commercializing WAKIX (pitolisant) for narcolepsy and expanding into rare epilepsy and neurobehavioral disorders. Net product revenue from WAKIX was $868.5 million in 2025; WAKIX represented 98% of total revenue. The company's core... Read more
Wait for pullback to $30.14. Recent C-suite change — blocks BUY_NOW at $32.24. Engine's entry $30.14 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: WAKIX (98.0%); Concentration risk — Supplier: Bioprojet. Chart setup: Death cross but MACD improving, RSI 59. Growth is outpacing valuation and the technical setup has confirmed a breakout above resistance (PEG 0.04, quality 7.8/10, growth 8.3/10). | News modifier -1 (STRONG_BUY_NOW → STRONG_BUY_WAIT) Score 6.6/10, moderate confidence.
Passes 8/10 gates (positive momentum, favorable risk/reward ratio, clean insider activity, positive momentum, news events none recent, earnings proximity 62d clear, semi cycle peak clear, materials cycle peak clear). Suitability: aggressive.
Recent developments
updated 2026-06-03Recent Developments — Harmony Biosciences Holdings, I
Latest news
- NEWS Harmony Biosciences to Participate in Upcoming Investor Conferences - Business Wire — Business Wire neutral
- NEWS Harmony Biosciences to Participate in Upcoming Investor Conferences - Yahoo Finance — Yahoo Finance neutral
- NEWS Oppenheimer raises Harmony Biosciences stock price target on patent strength - Investing.com UK — Investing.com UK positive
- NEWS Harmony Biosciences (HRMY) Is Up 9.7% After New CFO Hire And Reiterated 2026 Guidance – Has The Bull Case Changed? - sim — simplywall.st positive
- NEWS AQR Small Cap Multi-Style Fund's Harmony Biosciences Holdings Inc(HRMY) Holding History - GuruFocus — GuruFocus neutral
Generated 2026-06-03T18:16:48Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductWAKIX98%10-K Item 1A: 'We are substantially dependent on the commercial success of our only approved product, WAKIX.'
- HIGHSupplierBioprojet10-K Item 1A: 'We rely on our license agreements with Bioprojet to provide rights to the core intellectual property relating to pitolisant, and any termination or loss of significant rights under the agreement would adversely affect our development and/or commercialization of pitolisant.'
Material Events(8-K, last 90d)
- 2026-04-14Item 5.02MEDIUMSandip Kapadia, CFO, stepping down effective April 14, 2026 to pursue other career opportunities. Glenn Reicin appointed CFO effective same date. Clean handoff with named successor.SEC filing →
- 2026-04-02Item 5.02LOWPeter Anastasiou appointed Senior EVP and COO effective April 2, 2026. In connection with appointment, Anastasiou resigned as Class III Board director, also effective April 2, 2026. No disagreement cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait for pullback to $30.14. Recent C-suite change — blocks BUY_NOW at $32.24. Engine's entry $30.14 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Product: WAKIX (98.0%); Concentration risk — Supplier: Bioprojet. Chart setup: Death cross but MACD improving, RSI 59. Growth is outpacing valuation and the technical setup has confirmed a breakout above resistance (PEG 0.04, quality 7.8/10, growth 8.3/10). | News modifier -1 (STRONG_BUY_NOW → STRONG_BUY_WAIT) Target $38.60 (+19.7%), stop $28.27 (−14.0%), Setup A.R:R 3.9:1. Score 6.6/10, moderate confidence.
Take-profit target: $38.60 (+23.4% upside). Target $38.60 (+19.7%), stop $28.27 (−14.0%), Setup A.R:R 3.9:1. Stop-loss: $28.27.
Concentration risk — Product: WAKIX (98.0%); Concentration risk — Supplier: Bioprojet; Consecutive earnings misses (3).
Harmony Biosciences Holdings, I trades at a P/E of 12.5 (forward 5.5). TrendMatrix value score: 8.9/10. Verdict: Buy (Wait for Entry).
17 analysts cover HRMY with a consensus score of 3.8/5. Average price target: $44.
What does Harmony Biosciences Holdings, I do?Harmony Biosciences is a neuroscience company commercializing WAKIX (pitolisant) for narcolepsy and expanding into rare...
Harmony Biosciences is a neuroscience company commercializing WAKIX (pitolisant) for narcolepsy and expanding into rare epilepsy and neurobehavioral disorders. Net product revenue from WAKIX was $868.5 million in 2025; WAKIX represented 98% of total revenue. The company's core IP is exclusively licensed from Bioprojet under two license agreements.